Dr. Seung Tae Lee
Claim this profileUniversity of Maryland/Greenebaum Cancer Center
Area of expertise
Relapse
Seung Tae Lee has run 2 trials for Relapse. Some of their research focus areas include:
Non-Hodgkin's Lymphoma
Seung Tae Lee has run 2 trials for Non-Hodgkin's Lymphoma.
Affiliated Hospitals
University Of Maryland/Greenebaum Cancer Center
University Of Maryland Greenebaum Comprehensive Cancer Center
Clinical Trials Seung Tae Lee is currently running
Venetoclax
for Relapsed Hairy Cell Leukemia
This phase II trial tests how well venetoclax works in treating patients with hairy cell leukemia that has come back after a period of improvement (relapsed). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival.
Recruiting
1 award
Phase 2
8 criteria
Selinexor + R-GDP
for Lymphoma
The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or chimeric antigen receptor T cell (CAR-T) therapy. This study consists of 3 arms each in Phase 2 and 3. Phase 2 portion of the study will assess the two doses of selinexor (40 milligram \[mg\] or 60 mg) in combination with R-GDP, for up to 6 cycles (21-day per cycle), followed by 60 mg selinexor single agent continuous therapy for those who have reached a partial or complete response. Phase 3 portion of the study will evaluate the selected dose of SR-GDP (identified in Phase 2) versus standard R-GDP + matching placebo, for up to 6 cycles (21-day per cycle), followed by placebo or 60 mg selinexor single agent continuous therapy for those who have reached partial or complete response.
Recruiting
0 awards
Phase 2 & 3
9 criteria
More about Seung Tae Lee
Clinical Trial Related
6 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Seung Tae Lee has experience with
- Obinutuzumab
- Rituximab
- Venetoclax
- CC-99282
- Tafasitamab
- Tazemetostat
Breakdown of trials Seung Tae Lee has run
Non-Hodgkin's Lymphoma
Chronic Lymphocytic Leukemia
Lymphoma
Hairy Cell Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Seung Tae Lee specialize in?
Seung Tae Lee focuses on Relapse and Non-Hodgkin's Lymphoma. In particular, much of their work with Relapse has involved MYC positive patients, or patients who are Bcl2 positive.
Is Seung Tae Lee currently recruiting for clinical trials?
Yes, Seung Tae Lee is currently recruiting for 3 clinical trials in Baltimore Maryland. If you're interested in participating, you should apply.
Are there any treatments that Seung Tae Lee has studied deeply?
Yes, Seung Tae Lee has studied treatments such as Obinutuzumab, Rituximab, Venetoclax.
What is the best way to schedule an appointment with Seung Tae Lee?
Apply for one of the trials that Seung Tae Lee is conducting.
What is the office address of Seung Tae Lee?
The office of Seung Tae Lee is located at: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland 21201 United States. This is the address for their practice at the University of Maryland/Greenebaum Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.